A Special Type of Government Scrutiny: Pharmaceutical Manufacturer Relationships with Specialty Pharmacies: Part 1

Manufacturer relationships with specialty pharma

Bloomberg Law article on government scrutiny of the relationship between manufacturers and specialty pharma

1000
pdf Download pdf (343.0 KB)

Related content

An area that has garnered considerable government scrutiny of late is the relationships between pharmaceutical manufacturers and specialty pharmacies. In this two-part series, Bloomberg Law explores the development of the specialty pharmacy market and the risks as-sociated with these relationships and outline reasonable controls to mitigate the risks based upon re-cent enforcement actions.

 

In Part I of this two-part series, the evolving and wide-ranging role of specialty pharmacies in the dispensing of specialty drugs is covered, and the increased risks of government scrutiny and enforcement around them. In Part II of the series, we will provide answers to the critical questions around how manufacturers might reasonably mitigate the risks associated with this area of business.

 

This article features REGINA GORE CAVALIERE and EVAN BARTELL.

Connect with us

 

Request for proposal

 

Submit

KPMG's new digital platform

KPMG International has created a state of the art digital platform that enhances your experience, optimized to discover new and related content.